CGEN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Compugen Ltd (CGEN) is not a strong buy for a beginner, long-term investor with $50,000-$100,000 available for investment. The stock shows no immediate positive trading signals, and while there is a promising analyst rating and a strong immuno-oncology pipeline, the recent financial performance and technical indicators suggest caution. Holding the stock or waiting for a clearer entry point is recommended.
The MACD is below 0 and negatively contracting, indicating a bearish momentum. RSI is neutral at 73.554, and moving averages are converging, suggesting no clear trend. The stock is trading near resistance levels (R1: 2.234, R2: 2.305), which may limit upward movement. Historical patterns indicate a high probability of short-term declines (-1.79% next day, -2.98% next week, -3.76% next month).
Analyst coverage initiated with a Buy rating and a $4 price target, citing a strong immuno-oncology pipeline and potential peak royalty streams of over $200M.
No recent news or significant trading trends from hedge funds or insiders. Financial performance in Q4 2025 shows a significant drop in net income (-1029.30% YoY) and EPS (-942.86% YoY), despite a revenue increase. Technical indicators and historical patterns suggest short-term price declines.
In Q4 2025, revenue increased significantly by 4477.29% YoY to $67.33M, but net income dropped sharply by -1029.30% YoY to $56.85M. EPS also fell by -942.86% YoY to 0.59. Gross margin improved to 94.75%, up 75.11% YoY, indicating operational efficiency.
H.C. Wainwright initiated coverage with a Buy rating and a $4 price target, citing the company's strong immuno-oncology pipeline and potential peak royalty streams exceeding $200M. This suggests a long-term growth opportunity, but the current price trend does not align with immediate gains.
